- Home
- NRC vs PBYI Comparison
NRC vs PBYI Comparison
Compare NRC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRC | PBYI |
|---|---|---|
| Founded | 1981 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.7M | 467.2M |
| IPO Year | 1997 | 2011 |
Fundamental Metrics
Financial Performance| Metric | NRC | PBYI |
|---|---|---|
| Price | $21.71 | $11.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 79.4K | ★ 322.5K |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | ★ 4707.69 | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | ★ $119,686,000.00 | $27,685,000.00 |
| Revenue This Year | $3.79 | N/A |
| Revenue Next Year | $8.35 | $1.33 |
| P/E Ratio | ★ N/A | $140.75 |
| Revenue Growth | ★ 1.81 | N/A |
| 52 Week Low | $11.32 | $4.58 |
| 52 Week High | $23.68 | $11.38 |
Technical Indicators
Market Signals| Indicator | NRC | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 63.64 |
| Support Level | $21.20 | $9.04 |
| Resistance Level | $21.83 | N/A |
| Average True Range (ATR) | 0.75 | 0.48 |
| MACD | 0.14 | 0.09 |
| Stochastic Oscillator | 87.38 | 76.56 |
Price Performance
Historical ComparisonAbout NRC National Research Corporation (Delaware)
NRC Health operates as a humanized healthcare and support organization. Its platform includes Listen, Understand, and Improve. The group provides solutions for Patient, Consumer, Employee, and Market experiences. The group's commitment to Human Understanding helps healthcare systems get to know the patients, families, consumers, employees, and communities it on a human level.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.